{"entity":{"id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of OH2+BS006 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","summary":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07382531 by Binhui Biopharmaceutical Co., Ltd., with 30 participants planned, started 2023-09-07 and due to reach its primary completion in 2027-12-31. Interventions recorded: OH2+BS006.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07382531","url":"https://clinicaltrials.gov/study/NCT07382531"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07382531","phase":"1/2","setting":"An Open-label, Dose-escalation Phase Ib/II Clinical Trial of Intratumoral Injection of OH2 Injection in Combination With BS006 Injection for the Treatment of Advanced Solid Tumors.","sponsor":"Binhui Biopharmaceutical Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct07382531/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/"}]}}